Literature DB >> 9184357

In-vitro susceptibility pattern of Candida lusitaniae and evaluation of the Etest method.

A Favel1, A Michel-Nguyen, C Chastin, F Trousson, A Penaud, P Regli.   

Abstract

The antifungal susceptibility of 35 Candida lusitaniae isolates was determined in vitro by the National Committee for Clinical Laboratory Standards (NCCLS) M27-P macrodilution methodology. All the isolates were susceptible to ketoconazole, itraconazole and fluconazole. Of the 35 isolates, eight (23%) were resistant to flucytosine. For amphotericin B, M27-P yielded a narrow range of MICs (0.06-0.5 mg/L). We therefore investigated the activity of this drug by reading MICs at 72 h and by using alternative media, namely casitone complex medium (CCM) and antibiotic medium 3 (M-3). Reading at 72 h did not generate reproducible results. CCM and M-3 provided better discrimination between the isolates but did not change the rank order of the MICs. We thus concluded that all the isolates were susceptible to amphotericin B. We also conducted an evaluation with the Etest method according to the manufacturer's instructions with RPMI 1640 agar, CCM and the alternative semi-synthetic medium (SSM). For RPMI 1640, agreements +/-2 dilutions were 58% for amphotericin B, 92% for flucytosine, 57% for ketoconazole, 92% for fluconazole and 74% for itraconazole. CCM did not improve the agreement rates between the two methods but it led to better growth of all the isolates. The suitability of SSM was pointed out with itraconazole. The poor agreement rates for amphotericin B and ketoconazole call for further evaluation of the Etest method to assess several drug-organism combinations.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9184357     DOI: 10.1093/jac/39.5.591

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  7 in total

Review 1.  Antifungal susceptibility testing: practical aspects and current challenges.

Authors:  J H Rex; M A Pfaller; T J Walsh; V Chaturvedi; A Espinel-Ingroff; M A Ghannoum; L L Gosey; F C Odds; M G Rinaldi; D J Sheehan; D W Warnock
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

2.  Evaluation of Etest method for determining fluconazole and voriconazole MICs for 279 clinical isolates of Candida species infrequently isolated from blood.

Authors:  M J Maxwell; S A Messer; R J Hollis; L Boyken; S Tendolkar; D J Diekema; M A Pfaller
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

3.  Alternative identification test relying upon sexual reproductive abilities of Candida lusitaniae strains isolated from hospitalized patients.

Authors:  F François; T Noël; R Pépin; A Brulfert; C Chastin; A Favel; J Villard
Journal:  J Clin Microbiol       Date:  2001-11       Impact factor: 5.948

4.  Rates and extents of antifungal activities of amphotericin B, flucytosine, fluconazole, and voriconazole against Candida lusitaniae determined by microdilution, Etest, and time-kill methods.

Authors:  Erika J Ernst; Keiko Yodoi; Ellen E Roling; Michael E Klepser
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

5.  Improved detection of amphotericin B-resistant isolates of Candida lusitaniae by Etest.

Authors:  F Peyron; A Favel; A Michel-Nguyen; M Gilly; P Regli; A Bolmström
Journal:  J Clin Microbiol       Date:  2001-01       Impact factor: 5.948

6.  Investigation of In Vitro Activity of Five Antifungal Drugs against Dermatophytes Species Isolated from Clinical Samples Using the E-Test Method.

Authors:  Ayse Esin Aktas; Nimet Yigit; Akin Aktas; Sultan Gamze Gozubuyuk
Journal:  Eurasian J Med       Date:  2014-02

7.  Correlation of in vitro itraconazole and fluconazole susceptibility with clinical outcome for patients with vulvovaginal candidiasis.

Authors:  Milce Costa; Xisto Sena Passos; André Thiago Borges Miranda; Rosane Silva Carneiro de Araújo; Claudete Rodrigues Paula; Maria do Rosário Rodrigues Silva
Journal:  Mycopathologia       Date:  2004-01       Impact factor: 2.574

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.